Patents by Inventor Shiro Shibayama
Shiro Shibayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9783609Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.Type: GrantFiled: December 29, 2014Date of Patent: October 10, 2017Assignees: ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
-
Patent number: 9701749Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.Type: GrantFiled: August 10, 2012Date of Patent: July 11, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Masamichi Imai
-
Publication number: 20170051060Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.Type: ApplicationFiled: August 2, 2016Publication date: February 23, 2017Applicants: ONO PHARMACEUTICAL CO., LTDInventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
-
Patent number: 9439962Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.Type: GrantFiled: January 19, 2016Date of Patent: September 13, 2016Assignees: Ono Pharmaceutical Co., Ltd.Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Patent number: 9402899Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.Type: GrantFiled: April 4, 2014Date of Patent: August 2, 2016Assignees: ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Patent number: 9393301Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1 PD-L2 are useful for cancer or infection treatment.Type: GrantFiled: January 19, 2016Date of Patent: July 19, 2016Assignees: ONO PHARMACEUTICAL CO., LTD., TASUKU HONJOInventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Publication number: 20160158356Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.Type: ApplicationFiled: January 19, 2016Publication date: June 9, 2016Applicants: ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
-
Publication number: 20160158355Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.Type: ApplicationFiled: January 19, 2016Publication date: June 9, 2016Applicants: ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
-
Publication number: 20150197572Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.Type: ApplicationFiled: March 4, 2015Publication date: July 16, 2015Applicants: Ono Pharmaceutical Co., LTD., Tasuku HONJOInventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
-
Patent number: 9073994Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.Type: GrantFiled: November 21, 2014Date of Patent: July 7, 2015Assignees: Ono Pharmaceutical Co., LTD.Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Patent number: 9067999Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.Type: GrantFiled: March 4, 2015Date of Patent: June 30, 2015Assignees: Ono Pharmaceutical Co., LTD.Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Publication number: 20150118234Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.Type: ApplicationFiled: December 29, 2014Publication date: April 30, 2015Applicants: TASUKU HONJO, ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku HONJO, Shiro SHIBAYAMA, Kazuhiko TAKEDA, Masayoshi MATSUO, Takao YOSHIDA, Masakazu MIYAMOTO
-
Publication number: 20150093380Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.Type: ApplicationFiled: November 21, 2014Publication date: April 2, 2015Inventors: Tasuku HONJO, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Patent number: 8951518Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.Type: GrantFiled: July 13, 2012Date of Patent: February 10, 2015Assignees: Ono Pharmaceutical Co., Ltd.Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
-
Patent number: 8871210Abstract: The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.Type: GrantFiled: November 8, 2013Date of Patent: October 28, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Masaya Kokubo, Motoyuki Tanaka, Hiroshi Ochiai, Yoshikazu Takaoka, Shiro Shibayama
-
Publication number: 20140314714Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.Type: ApplicationFiled: April 4, 2014Publication date: October 23, 2014Applicants: ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
-
Patent number: 8822459Abstract: The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.Type: GrantFiled: February 15, 2011Date of Patent: September 2, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Masaya Kokubo, Yoshikazu Takaoka, Shiro Shibayama
-
Publication number: 20140220021Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.Type: ApplicationFiled: August 10, 2012Publication date: August 7, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Masamichi Imai
-
Patent number: 8728474Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.Type: GrantFiled: December 2, 2010Date of Patent: May 20, 2014Assignees: Ono Pharmaceutical Co., Ltd.Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Patent number: 8680092Abstract: A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.Type: GrantFiled: February 24, 2006Date of Patent: March 25, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Hiroshi Ochiai, Akira Ohhata, Yoshikazu Takaoka, Shiro Shibayama